117041, г. Москва, а/я № --, Гулиев Эльдар Касумович
Classes
28
NICE Classification
игрушки мягкие;
жилеты для плавания;
чехлы специальные для лыж;
доски для серфинга;
лыжи для серфинга;
лыжи водные;
чехлы специальные для досок для серфинга;
боди-борды;
удочки рыболовные;
снасти рыболовные;
доски для сапсерфинга;
ремни для досок для серфинга;
поплавки для плавания;
доски с парусом для серфинга;
Domain names similar "SAVA"
News around "SAVA" trademark
News sentiment analysis powered by sentiment-insight.com
2023-07-29
positive
Top 12 Small-Cap Stocks With Highest Upside Potential
A small cap stock is defined as one whose market value sits between $300 million and $2 billion. Impinj, Inc. (NASDAQ:PI)'s biggest shareholder is Daniel Patrick Gibson's Sylebra Capital Management with an investment of $385 million. Ligand Pharmaceuticals Incorporated (NASdaq:LGND), Cassava Sciences, Inc (NASCAR:SAVA), and Piedmont Lithium Inc. are some top small stocks with high upside.
2023-06-12
negative
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Cassava Sciences (NASDAQ:SAVA) shareholders should be worried about its cash burn. Cash burn is the amount of money a company spends each year to fund its growth. Cassava Sciences' cash burn of US$70m is about 6.9% of its US$1.0b market capitalisation. It would probably be really easy for the company to fund another year's growth by issuing some new shares to investors.
2023-03-13
positive
Why Cassava Sciences Stock Is Surging After Hours - NewsBreak
Cassava Sciences Inc (NASDAQ: SAVA) shares are rising in extended trading Wednesday in the wake of recent insider buying.
2023-02-02
negative
MP Evans Group "fully expects" to continue growing in 2023
Cassava Sciences (NASDAQ: SAVA) is exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease. The market reacted quite negatively to the release of new data that management spun as being positive.
2023-02-01
negative
IIROC Trading Halt - XOP
Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. The biggest reason to sell Cassava stock: After an open-label phase 2 clinical trial of simufilam.
2023-01-09
positive
6 Favorite Biotech Bets For 2023
Cassava Sciences (SAVA) is a high risk, high reward clinical biotech company. Its flagship drug candidate is Simufilam — an Alzheimer’s drug. If it gets approved, it could easily become a multi-billion dollar drug.
Sign Up
